@article{d4eb63de480e47baad20d6972809f706,
title = "How to Manage and Monitor Cardiac Dysfunction in Patients With Metastatic HER2-Positive Breast Cancer",
keywords = "cardiac monitoring, cardiotoxicity, metastatic breast cancer, novel HER2 agents",
author = "Dent, {Susan F.} and Heather Moore and Priyanka Raval and Laura Alder and Avirup Guha",
note = "Funding Information: Dr Guha is supported by the American Heart Association Strategically Focused Research Network Grant in Disparities in Cardio-Oncology (847740 and 863620). Dr Dent has received research funding and honoraria from Novartis; and is a consultant for AstraZeneca; Dr Moore is a consultant for Novartis, Daiichi Sankyo, AstraZeneca, SeaGen, and Eli Lilly. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.",
year = "2022",
month = sep,
doi = "10.1016/j.jaccao.2022.06.002",
language = "English (US)",
volume = "4",
pages = "404--408",
journal = "JACC: CardioOncology",
issn = "2666-0873",
publisher = "Elsevier Inc.",
number = "3",
}
